Clark Capital Management Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Clark Capital Management Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-296	Closed	-$311K	–	448
2024 Q3	$311K	Buy	296 +31	+12%	+$34.5K	﹤0.01%	360
2024 Q2	$279K	Buy	+265	New	+$257K	﹤0.01%	355
2021 Q1	–	Sell	-41,521	Closed	-$20.1M	–	363
2020 Q4	$20.1M	Buy	41,521 +9,711	+31%	+$5.24M	0.33%	130
2020 Q3	$17.8M	Sell	31,810 -18,049	-36%	-$10.9M	0.34%	130
2020 Q2	$31.1M	Buy	49,859 +10,311	+26%	+$5.85M	0.58%	46
2020 Q1	$19.3M	Buy	+39,548	New	+$16.3M	0.49%	72
2017 Q3	–	Sell	-16,089	Closed	-$7.9M	–	323
2017 Q2	$7.9M	Buy	16,089 +11	+0.1%	+$4.81K	0.31%	97
2017 Q1	$6.23M	Buy	+16,078	New	+$5.96M	0.28%	106

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Clark Capital Management Group's REGN Position: Q4 2024 in Review

Clark Capital Management Group sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 296 shares — an estimated $311K sold.

Clark Capital Management Group first reported a position in REGN in Q1 2017 and held it in 8 quarters. The position peaked at $31.1M in Q2 2020. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Clark Capital Management Group reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Clark Capital Management Group sold 296 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $311K.
Clark Capital Management Group first reported a position in Regeneron Pharmaceuticals in Q1 2017 and held it in 8 quarters.
Clark Capital Management Group's Regeneron Pharmaceuticals position peaked at $31.1M in Q2 2020.
1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Clark Capital Management Group's 13F filing for Q4 2024, filed 14 Feb 2025.